We are a clinical stage biopharmaceutical company, based in Munich, developing first-in-man, first-in-class, targeted therapies for cancer, inflammation and tissue regeneration.
Our proprietary platform technology is based on next generation engineered cell-based therapeutics, which offer considerable advantages over existing technologies. Our lead product is already in Phase II, for the treatment of gastrointestinal tumors.
In addition, we provide our know-how, expertise and GMP-certified facilities to offer development, optimisation, scale up and GMP manufacturing services to industry and academic partners around the world. apceth was one of the very first companies in Germany to receive a manufacturing license in 2010 for pharmaceutical production of somatic cell therapeutics and tissue procurement according to the German Medicines Act (AMG).
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.